ÀËÅç(examination) »PÀË´ú(testing) ¨â¦r±±qªí±¬Ý¦ü¬Û¦P¡A¹ê«h¦b¬ì¾Ç¤Wªº·N¸q¡BÂå¾Ç¤èªk¤Î¤º®e¬Ò¦³ÅãµÛ¤£¦P¡C
Âå¾Ç¤Wªº¡uÀËÅç³ø§i¡v¤£µ¥¦P©ó¡uÀË´ú³ø§i¡v¡A¨ä³Qn¨D©Ò»Ý¥X¨ãªº³ø§i¤º®e¤Îµ¥¯Å¥ç¤£¦P¡C¨Ì¾Ú2005 ¦~°ê»Ú¼Ð·Ç²Õ´(International Organization for Standardization,
ISO) µo¦æ¤§ISO 9000 «~½èºÞ²zªº³N»y¤Î©w¸q¡A
¡uÀËÅç¡v¬°ÂÇ¥ÑÆ[¹î»P§PÂ_©Ò¶i¦æªº²Å¦X©Êµû¦ô¡A¾A·í®É¥iµ²¦X¶q´ú¡B´ú¸Õ¤Î¶q³Wp´ú©Ò¶i¦æªº²Å¦X©Êµû»ù¡C¬Û¹ï¦Ó¨¥¡A
¡uÀË´ú¡v«üªº¬O«ö·Óµ{§Ç½T©w¦X®æµû©w¹ï¶Hªº¤@өΦhÓ¯S©Êªº¬¡°Ê¡C
¡uÀËÅç¡v¤Î¡uÀË´ú¡v¨âªÌ¬Û¤ñ¡A¡uÀËÅç¡v«µø²Å¦X©Ê¡A¤£¶È´£¨Ñµ²ªG¡A§ón»P³W©wn¨D¶i¦æ¤ñ¸û¡A¶i¦æ¦X®æ»P§_¤§§P©w¡F
¡uÀË´ú¡v¬°«ö·Ó³W©wµ{§Ç¶i¦æªº¬¡°Ê¡Aªx«ü¤@¶µ§Þ³N¬¡°Ê¡A¶È´£¨Ñµ²ªG¡A¤£¶i
¦æ¦X®æ»P§_¤§§P©w¡C
®Ú¾ÚISO 15189 Âå¾Ç¹êÅç«Ç¡X«~½è»P¯à¤On¨D¤§©w¸q¡A
ÀËÅ笰¥H´ú©w¬Y¤@©Ê½è¤§¼ÆÈ©Î¯S©Ê¬°¥Øªºªº¤@®M§@·~¡A¦ÓÂå¾Ç¹êÅç«ÇªA°È¤º®e¥]¬AÀËÅ窺¥Ó½Ð¡B¯f¤H·Ç³Æ¡BÃѧO¡BÀËÅ馬¶°¡B¹B°e¡BÀx¦s¡B³B²z¡BÀËÅç¡B¥H¤Î«áÄòµ²ªGªº½T»{¡B¸ÑÄÀ¤Î³ø§i¡A¥B·í°ê®aªk³W³\¥i®É¡AÂå¾Ç¹êÅç«ÇªºªA
°ÈÁÙ¥]¬AÀËÅç¿Ô¸ß»P¥D°Ê°Ñ»P¬ÛÃö¯e¯f¹w¨¾¡C
¥Ø«e¡AÅé¥~¶EÂ_¸Õ¾¯¡A¥]§t®ø¶OªÌ¥iª½±µÁʱo¤§¡uÀË´ú¡v²£«~¬Ò³QFDAµø¬°ÂåÀø¾¹§÷(medical devices) ºÞ²z¡AÀ³³Qµø¬°ÀË´ú¤èªk¡F
¦Ó¹³¬O¬ü°ê¡uÀËÅç¡vªA°È´N»Ýn¥Hªk«ßºÊºÞ¡A¡uÀËÅç¡vªA°È»Ý¦b²Å¦XÁ{§É¹êÅç«Ç§ï¶i×¥¿®×(Clinical Laboratory Improvement Amendments, CLIA) ¸ê®æ¤§¹êÅç«Ç¤è¯à¶i¦æ¡A©Î¬Y¨Ç°ê®a¥H¬Fµ¦³W½d¡A¡uÀËÅç¡vªA°È»Ý¦b¨ú±o°ê»ÚÂå¾Ç»â°ì¨ã¦³¸Ó¶µªA°È»{ÃÒ¸ê®æ¤§¹êÅç«Ç¬°¤§¡C¨Ò¦p¡GªÍÀùªí¥Ö¥Íªø¦]¤l¨üÅé(EGFR) ¬ðÅÜÅé¥~¶EÂ_©Ò´£¨Ñªºµ²ªG¡A¦]¬°nÀ³¥Î©ó«D¤p²ÓMªÍÀù¯f¤Hªº¯S©wÂåÀø¥Î³~¡]¦p¡G¬D¿ï¾A¦X¶i¦æ¼Ð¹vÃĪ«ªvÀø¡^¡A«hÀ³¸Óµø¬°ÀËÅçªA°È¡C
®Ú¾Ú¬ü°ê½Ã¥Í¤Î¤½¦@ªA°È³¡(U.S. Department of Health and Human Services)ªºÂ²¤¶¡A°ò¦]ÀË´ú(genetic testing)«Y«ü§Q¥Î¥Íª«§Þ³N§ä¥X¬V¦âÅé¡B°ò¦]¡B³J¥Õ½èÅܲ§¡A¨äÀË´úµ²ªG¯à§@¬°ÂåÀø¤W½T»{©Î±Æ°£ºÃ¦ü¿ò¶Ç±¡§Î(condition)¡A©Î¨ó§UÂåÀø¤Wµû¦ôÓ¤H¥¼¨Ó¿©±w¿ò¶Ç©Ê¯e¯f(disorder)¤§¥i¯à©Ê¡A©Ò¥H«ö·Ó¤Wz©w¸qÀ³¸ÓÄÝ©ó¡¨Âå¾ÇÀËÅ硨 ¡C
°ò¦]ÀËÅç(«D°ò¦]ÀË´ú)¥i¥H¨Ì·Ó¨Ï¥Î®É¾÷¡BÀËÅç¥Øªº¨Ó°Ï¤À¡A
¤£¦P¤åÄm¹ï°ò¦]ÀËÅç¤]¦³¤£¦Pªº¤ÀÃþ¡A±q¼s¸qªº¡u°·±d¬ÛÃö¡v(health-related)¡A¦p¡G³æ°ò¦]Åܲ§¿ò¶Ç¯e¯f- ¯áÅè¤p¸£µäÁY¯gÀËÅç¡B¦h°ò¦]Åܲ§¿ò¶Ç¯e¯f- ¤ß¦åºÞ¯e¯fÀËÅç¡B©ÊÁp¿ò¶Ç©Ê¯e¯f-X¬V¦âÅé¯Ü§é¯g¡B¾AÃĩʰò¦]- ªÍÀù¼Ð¹vÃĪ«ÃĪ«°ò¦]ÀËÅç¡A»P¡u«D°·±d¬ÛÃö¡vÀËÅç¡G·¹·½°ò¦]ÀËÅç¡B¹B°Ê°ò¦]ÀËÅç¡B©Ê®æ¯S½è°ò¦]ÀËÅç¡B¦¨¥\¯S½è°ò¦]ÀËÅçµ¥¡F
¥t¥~¤ñ¸û±`¥Îªº°ò¦]ÀËÅ礧¤ÀÃþ¡A¬O¥H¡uÂåÀø¥Øªº¡v(medical purpose)¡A¦p²£«e°ò¦]ÀËÅç¡Bµo¯f«e°ò¦]ÀË´ú(pre-symptomatic
testing)¡B¯e¯f·ÀI¹w´ú°ò¦]ÀË´ú(predictive testing)¡A»P¡u«DÂåÀø¥Øªº¡v(non-medical purpose)¡A¦pªkÂåŲ©w¡B¿Ë¤lŲ©w°µ¤ÀÃþ¡C
¼w°ê©ó2010¦~2¤ë¥Í®Ä¤§¡u¤HÃþ°ò¦]ÀËÅçªk¡v(Human
Genetic Examination Act)±N¡uÂåÀø¥Øªº¡vªº°ò¦]ÀËÅç(genetic examination for medical
purposes)©w¸q¬°¥ô¦ó¨ã¦³¶EÂ_(diagnostic)©Î¹w´ú(predictive)©Ê½è¤§°ò¦]ÀË´ú¡A¹ï¡u¶EÂ_°ò¦]¡v¤Î¡u¹w´ú°ò¦]¡vÀËÅç¤À§O¦CºÞ¡A©ú½T³W½d¬ÛÃö±Mªù¤Hû¤§Â¾·~±ø¥ó¡A¤Àz¦p¤U¡G
¤@¡B ¡u¶EÂ_°ò¦]¡vªº°ò¦]ÀËÅç¶È¥ÑÂå®v¶}¥ß¡A¬°¥]§t¤U¦C¥ô¤@¥Øªº¤§°ò¦]ÀËÅç¡G
1.
½T»{¤w¦s¦b¤§¯e¯f©Î°·±d±¡§Î¡F
2.
µû¦ô¬O§_¦³¥ô¦ó¥i¯à¾ÉP¯e¯f©Î°·±d°ÝÃDªº°ò¦]¯S¼x»P¥~¦b¦]¤l¨Ã¦s¡F
3.
µû¦ô¬O§_¦³¥ô¦ó¥i¯à¼vÅTÃĪ«§@¥Îªº°ò¦]¯S¼x¡F
4.
µû¦ô¬O§_¦³¥ô¦ó¥i¯à§¹¥þ©Î³¡¥÷¹w¨¾¯e¯f©Î°·±d°ÝÃDµo¥Íªº°ò¦]¯S¼x¡C
¤G¡B ¡u¹w´ú°ò¦]¡vªº°ò¦]ÀËÅç¡A¶È¥Ñ¨ã»{ÃÒ¸ê®æ¤§¤HÃþ¿ò¶Ç±M¬ìÂå®v©Î¨ä¥L¦b¨ä¥L±M¬ì»â°ì¨ú±o°ò¦]ÀËÅç¸ê®æªºÂå®v¶}¥ß¡A¬°§t¤U¦C¥ô¤@¥Øªº¤§°ò¦]ÀËÅç¡G
1.
¥ô¦ó¥¼¨Ó¥i¯à²£¥Í¤§¯e¯f©Î°·±d°ÝÃD¡F
2.
±a¦³·|¹ï«á¥N³y¦¨¯e¯f©Î°·±d°ÝÃD¤§°ò¦]¯S¼x¡C
¸Óªk³W©w¡A¦b°õ¦æ°ò¦]ÀËÅç©MÀËÅé±Ä¶°«e¡A»Ý§iª¾¤Uz¤º®e:
1.
ÀËÅ示®e¡B
2.
ÀËÅçµ²ªG»P
3.
°·±d·ÀIªºÃö«Y¡B
4.
ÀËÅç¾A¥Î½d³ò¡B
5.
¨ú®øÀËÅ礧Åv§Qµ¥¤º®e¡A
¨Ã¨ú±o¨üÀ˪̪º®Ñ±¦P·N®Ñ«á©l¥i¬°¤§¡A¨Ã»Ýn´£¨Ñ¨üÀ˪̸Բӧ¹¾ãªº¿ò¶Ç¿Ô¸ß(genetic counselling)¡F°£¼w°ê¥~¡A¼Ú¬w¨ä¥L°ê®a¡A¦p¡G¶ø¦a§Q(Gene
Technology
Act)¡B·ç¤h(Federal
Act on Human Genetic Testing, GUMG)µ¥°ê¬Ò±Ä±Mªk¼Ò¦¡³W½d ÂåÀø¥Î©Î°·±d¬ÛÃö°ò¦]ÀËÅç¡C
¶ø¦a§Qªº°ò¦]§Þ³Nªk(Gene Technology Act) «hn¨D¾Þ§@°ò¦]ÀËÅç¾÷ºc»Ý«ü¬£¨ã¦³¤HÃþ¿ò¶Ç¾Ç±M·~¸ê®æ©ÎÂå¾Ç¶EÂ_¹êÅç«Ç¸ê®æ©Î¨ä¥L¨ü¹LÂå¾Ç¡B¿ò¶Ç¾Ç±M·~°V½m¤§¤Hû°µ¬°¹êÅç«Ç¥DºÞ(laboratory manager)¡At³dºÞ²z¹êÅç«ÇªºÀËÅç«~
½è»P¤Hû±Ð¨|°V½m¡C
«nÁúªº¥Íª«Û²z»P¥Íª«¦w¥þªk(Bioethics and Biosafety Act) «h³W©w¡A°õ¦æ
°ò¦]ÀËÅç©Îª½±µ¨ú±o¯f¤HÀËÅé¶i¦æ°ò¦]¬ã¨s¡A¶ÈÂåÀø¾÷ºc°õ¦æ»P¯e¯f¶EÂ_¦³Ãöªº°ò¦]ÀËÅç¡A¥B»Ý¦V¥DºÞ¾÷Ãö§Y°·±d»PºÖ¬ç³¡(Ministry of Health and Welfare) ³ø³Æ¡C³o¨Ç³£¬OÂåÀø¥Øªºªº°ò¦]ÀËÅç¡A¥ý¶i°ê®a©Òn¨Dªº³W®æ¡C
ªº°ò¦]ÀËÅç¡C
¿D¬w°ê®a°·±dº[ÂåÃĬã¨s©eû·|(National Health and Medical Research Council, NHMRC)±N¡uÂåÀø¥Øªº¡vªº°ò¦]ÀËÅç°ò¦]ÀËÅç¤À¦¨¤U¦C´XÃþ¡G
1.
Åé²ÓM°ò¦]ÀË´ú(
somatic genetic testing)¡G
ÀËÅç§t²ÓM²Õ´¡]³q±`¬°Àù¯g¡^¦b¤ºªº«D¿ò¶Ç©Ê¬ðÅÜ¡AÀËÅçµ²ªG¥i¯à¬°¶EÂ_¥Øªº©Î¬OÀ°§UÂåÀøºÝ¿ï¾Ü¦X¾AªºªvÀø¤è¦¡¡C
2.
¶EÂ_©Ê¿ò¶ÇÅܲ§°ò¦]ÀË´ú(diagnostic
testing for heritable mutations)¡G
¥Î©óÀËÅç¥X¾ÉP¤wµo¯S©w¯e¯f¤§¿ò¶Ç©Ê°ò¦]¬ðÅÜ¡A³q±`¥]§t¤@өΦhÓ°ò¦]Åܲ§¡C
3.
¹w´ú©Ê¿ò¶ÇÅܲ§°ò¦]ÀË´ú(predictive
testing for heritable mutations)¡G
¤]³QºÙ¬°µo¯f«e´ú¸Õ(pre-symptomatic types)¡A¥Î©óÀËÅç©|¥¼µo¯f«e¡A±q¿Ë¥N¿ò¶Çµ¹¤U¤@¥N¤§¥Í´Þ²ÓM¨t¬ðÅÜ(germline mutation)¡A¯e¯fªº·ÀI®Ú¾Ú°ò¦]¬ðÅܱ¡§Î¡B®a±Ú¥v¡A¦Ó¦³©Ò¤£¦P¡C
4.
¿ò¶Ç©ÊÅܲ§±a¦]ªÌÀË´ú(carrier
testing for heritable mutations)¡G
ÀËÅç¨S¦³¾ÉP¿©¯f·ÀI¤§°ò¦]¬ðÅÜ¡B¦ý¥i¯à·|¼W¥[¤U¤@¥N¤§¿©¯f·ÀI¤§¿ò¶Ç©Ê¯e¯f¡C
5.
ÃĪ«°ò¦]¾ÇÀË´ú(pharmacogenetics testing)¡G
ÀËÅç¥i¯à¨Ó¦ÛÅé²ÓM©Î¥Í´Þ²ÓM·|§ïÅÜÃĪ«¥NÁªº°ò¦]Åܲ§¡C
«D¡uÂåÀø¥Øªº¡vªº¡u®ø¶OªÌ°ò¦]ÀËÅç¡v(Direct to Consumer, DTC)
¦]¬°°ò¦]ÀËÅç¦b¯e¯f¹w¨¾¡B¿zÀË¡B¶EÂ_¤ÎªvÀøµ¥¦U¶¥¬q¬Ò§êºt«n¨¤¦â¡A¥þ²y¥«³õ¤j´T¦¨ªø¡A¥B¦bÁ{§É»â°ìªºÀ³¥Î»á¨ã¼ç¤O¡A¦]¦Ó·~¬É¼®¤O©óµo®i¡u®ø¶OªÌ°ò¦]ÀËÅç¡v(Direct to Consumer, DTC)ªº°Ó·~¼Ò¦¡¡A ½dÃ¥¥]§t¡u°·±d¬ÛÃö¡v(health-related)»P¡u«D°·±d¬ÛÃö¡v(non-health-related)
ÀËÅç¶µ¥Ø¡C®Ú¾Ú¬ü°ê¹«~¤ÎÃÄ«~ºÊ·þºÞ²z§½(U.S. Food and Drug Administration,
FDA) ©w¸q¡A¥¼¸g¥ÑÂåÀø°|©ÒÂ卯¤Hû¡Aª½±µ¥Ñ°ò¦]ÀËÅ礽¥q±¦V¨üÀ˪̩Ҷi¦æªº¦Û¶OÀËÅç¬Ò¬°¡u®ø¶OªÌ°ò¦]ÀËÅç¡v¡A¨Ò¦p:2018¦~¬ü°êª¾¦W°ò¦]ÀËÅ礽¥q¡u23andMe¡v¡A¬°ºÓ³QFDA§åã¥iª½±µ´£¨Ñ®ø¶OªÌÀËÅçªA°Èªº°Ó·~¾÷ºc¡A¶i¦æ¥]§tªü¯÷®üÀq ¯g¡B¤Úª÷´Ë¤ó¯g¦b¤ºªº10¶µ¯e¯f°·±d·ÀIµû¦ô
(23andMe personal Genome Service Genetic Health Risk Test)¡B¨ÅÀù°ò¦]·ÀIÅç¤Î°ò¦]¥NÁ¯S©wÃĪ«¯à¤OÀËÅç¡C¥H¸Ó¤½¥qªº¡u¨ÅÀù°ò¦]·ÀIÀËÅç(23andMe Personal Genome Service Risk Report for BRCA1/BRCA2,
Selected Variants)¡v¬°¨Ò¡A¨ä¥Dn¥Î©óÀËÅç¼w¨tµS¤Ó¤H¦å²Î (Ashkenazi
Jewish)±wªÌ¤¤³Ì±`¨£ªºBRCA1©MBRCA2°ò¦]ªº¤TÓÅܲ§¦ìÂI¡A®Ú¾Ú¸Ó²£«~¥é³æ¡A¦¹ÀËÅçÂå§÷µLªk¶EÂ_©Î¥ô¦ó¨ä¥L°·±dª¬ªp¡A¥B¤£À³³Q¥Î¨Ó°µÂåÀø¨Mµ¦¡A¥çµLªk¨ú¥NÂåÀø¤Hûªº¿zÀË«ØÄ³©Î«áÄò°lÂÜ¡Cȱoª`·Nªº¬O¡AFDA§åã¸Ó²£«~¬°¡u»Ý¿í´`¯S§On¨D(special controls)ªº¤G¯ÅÂåÀø¾¹§÷(class II medical device)¡v¡A¸Ó²£«~»Ý´£¨Ñ®ø¶OªÌ¥]§tÀËÅ礧°ò¦]Åܲ§¦ìÂI¡B»¡©ú¸Ó²£«~«D¨Ñ¯e¯f¶EÂ_©ÎªvÀø¨Mµ¦¥Îµ¥»PÀËÅç·Ç½T©Ê¡B¨î©Ê¬ÛÃö°T®§¡A¥H½T«O®ø¶OªÌÁA¸Ñ¸Ó²£«~¦³®Ä©Ê»P¦w¥þ©Ê¡F¤]´N¬O¬ü°êFDA»{¥i¸ÓÀËÅçÂå§÷¨Ï¥Î·N¹Ï©Ò±a¨Ó¤§¯q³B¶W¹L¹ïÀËÅç»{ª¾¤£¥¿½T¡B¿ù»~³ø§i¤Î¿ù»~¸ÑÄÀ¤§·ÀI¡A±©¬ü°êFDAÅý®ø¶OªÌ¦Û¦æ¨M©w¡u®ø¶OªÌ°ò¦]ÀËÅç¡v(Direct to Consumer, DTC)ªº°Ó·~¼Ò¦¡¬O§_±Ä¥Î¡A¦Û¦æ©Ó¾á·ÀI¡A¦ýFDA¨Ã¤£¹ï¡u®ø¶OªÌ°ò¦]ÀËÅç¡vªºÀËÅçµ²ªGI®Ñ¡C
¥xÆW²{¦æªk³W»Pµo®i¤è¦V¤§¬Ù«ä
½Ã¥ÍºÖ§Q³¡±N®Ú¾ÚÂåÀøªk²Ä62±ø²Ä2¶µ³W©w¡A©ó2019¦~¶}©l±À°Ê¹êÅç«Ç¶}µoÀË´ú¤§·sºÞ²z¾÷¨î¡A¥Dn³W½d¬O¥H·|¼vÅT«áÄòÂåÀø¦æ¬°ªº¬ÛÃöÂåÀøÀËÅ笰¥D¡A¤]´N¬O¥H¡uÂåÀø¥Øªº¡vªº°ò¦]ÀËÅçªA°È¡A¦Ü©ó®ø¶OªÌ°ò¦]ÀËÅ窺¶µ¥Ø«h¼È¤£¦C¤J¦Ò¼{ºÞ²z¡C¹ï©óÂåÀø¥Øªºªº°ò¦]ÀËÅ礧ªì¨BÀÀ©wªººÞ²zì«h¥]§t¥H¤U´XÂI¡G
1.
¤£¤¹³\«DÂåÀø¾÷ºc¹ï®ø¶OªÌª½±µ¶i¦æ¡uÂåÀø¥Øªº¡vªº°ò¦]ÀËÅçªA°È¡C
2.
«DÄÝÂåÀø¾÷ºc¤§¹êÅç«Ç¡A»Ý±µ¨üÂåÀø¾÷ºc¤§©e°U«á¡A¤~¯à¬I¦æÂåÀø¥Îºë·ÇÂåÀø¤À¤lÀË´ú¹êÅç«ÇÀË´ú»PªA°È(LDTS)¡C
3.
±µ¨üÂåÀø¾÷ºc©e°UÀË´úªº¹êÅç«Ç¡A»Ý¸g¹L¤¤¥¡¥DºÞ¾÷Ãö©Î»{¥i³æ¦ìªº»{ÃÒ¡C
4.
¹êÅç«ÇY´£¨Ñ§PŪ³ø§iªºªA°È¡A¶·¥Ñ¡uÂå®v¡v°õ¦æ¡C
5.
©ñ¼e¬ÛÃöÂ卯¤Hû°õ·~³õ©Òµn°O¦aÂI¨î¡C
6.
©w¸q¤Îµû¦ô·í¹H¤Ï¯SºÞ¿ìªk¬ÛÃö³W½d®É¡A¥i¯à¹H¤Ïªºªk³W¡]¦pÂåÀøªk¡BÃĨƪk¡BÂåÀøÀËÅç®vªkµ¥¡^¤Î»@«h¡C
±q¤Wz¥xÆW·í§½©Ò¤½§iªººÞ²zì«hªº¤j¤è¦V¦ü¥G¥i¿s¨£¡A¥xÆW¥¼¨Ó±N¥i¯à°Ï¤À¬°ÂåÀø¥Øªºªº°ò¦]ÀËÅç»P®ø¶OªÌ°ò¦]ÀËÅç¡A¨ä©Ò¨ü¨ìªº³W½d±j«×¦³©Ò¤£¦P¡CµM¦Ó¡A¬O§_¯à¶È¥HÂåÀø¥Øªº§@¬°¹º¤À¼Ð·Ç¡A¹ê¦³ºÃ¸q¡A¨Ò¦p¥Á²³±µ¨ü®ø¶OªÌ°ò¦]ÀËÅç«á¡A¹ï©óÀËÅçµ²ªG¦p¦³ºÃ°Ý¡A¤´µM·|´M¨DÂåÀø¿Ô¸ß¡A¦ÓÂå®v«o¦³¥i¯à¨Ì¾Ú¦¹ÀËÅçµ²ªG¶i¦Ó¼vÅT«áÄòÂåÀø§PÂ_¡C
¦AªÌ¡AÂåÀø¥Øªºªº°ò¦]ÀËÅç»P®ø¶OªÌ°ò¦]ÀËÅç¤GªÌ¤§ÀËÅç«~½è¡Bµ²ªG·Ç½T©Êµ¥¬O§_·|¦³µ{«×¤W®t²§¡A¸Ó®t²§¦pªG¾ÉPÀËÅçµ²ªG¥¢·Ç¥X²{°°¶§©Ê¡B°°³±©Ê¾÷²v¼W¥[¡A¤Ï¦Ó¨Ï¥Á²³²£¥Í¤£¥²n¤§®£·W¡A¦ý¦pªG·Ç½T©Ê¤Î«~½è¨ÃµL®t²§¡A«h¦ó¥H¤GªÌ©Ò¨ü³W½d±j«×¤£¦P¡C
¦p¥Hªk³W¾A¥Î±Æ[¹î¡AÂåÀø¥Øªºªº°ò¦]ÀËÅç¥i¯à¯A¤ÎÂåÀøªk¡BÃĨƪk©ÎÂåÀøÀËÅç®vªkµ¥¡A¦ý®ø¶OªÌ°ò¦]ÀËÅç«o¥i¯à¦b©w©Ê¤WÄÝ©ó®ø¶O¦æ¬°¡A¦Ó¯A¤Î¥Áªk¤Î®ø¶OªÌ«OÅ@ªk¡A¤Ï¦Ó³WÁ×ÂåÀø¬ÛÃöªk³W¤§¾A¥Î¡A³y¦¨¥»½è¦P¼Ë¬O°ò¦]ÀËÅç¡A«o¦]¨ä¬O§_¨ã¦³ÂåÀø¥Øªº¡A³y¦¨ªk³W¾A¥Î¦³©Ò¤£¦P¡A¥¼¨Ó¥ç®£¥Íª§Ä³¡C
¬ü°ê¦³¬ã¨sÅã¥Ü¡A¬ù¤»¦¨±µ¨ü¡u®ø¶OªÌ°ò¦]ÀËÅç¡v(Direct to Consumer, DTC)ªº¨üÀ˪̪í¥Üpµe»P¨ä®a®xÂå®v°Q½×ÀËÅçµ²ªG¡A¹w´Á±N¼W¥[¬Ý¶E®É¶¡»P¨ä¥LÂåÀø¸ê·½¨Ï¥ÎÀW²v¡A³y¦¨¤£¥²nªºÂåÀø¸ê·½®ö¶O¡C¥Ø«e°ò¦]ÀËÅç»P¿ò¶Ç¯e¯fÃö«Y¤´ÄÝ©óµo®i¤¤¤§·s¿³¬ì§Þ»Pª¾ÃÑ¡A°w¹ï¦¹¤@°Ó·~¼Ò¦¡¡A¨äÀËÅçµ²ªG¥¿½T©Ê¡B¨üÀ˪̹ïÀËÅç°Ó«~¤ÎÀËÅçµ²ªGªº»{ª¾¥¿½T©Ê¡B©M±M·~ªº¿ò¶Ç¿Ô¸ß¥²n©Ê¡A³£»ÝnÂÔ·Vµû¦ô¡FÀHµÛ¬ì§Þªº¶i¨B¡B¸ê°Tªº´¶¤Î¡A°ò¦]ÀËÅç±q¥H©¹ªºÂåÀø±M·~¾É¦V¨«¨ìÅU«È¿ï¾Ü¾É¦V¡A¦UÃþ°ò¦]ÀËÅç¦b¤£¦P±¡¹Ò¤U¥i¯à§êºt¤£¦Pªº¥\¯à¡A±q¹w´ú¡B¿zÀË¡B¶EÂ_¡BªvÀø¦U¶¥¬q³£À³¸Ó¦³¨äÀËÅçÀu¶Õ»PÀ³¥Î¨î¡C
¥¼¨Ó¡u°ò¦]ÀËÅç¡vªk¨î³W½d¤§«Øºc¡Aº¥ýÀ³¦Ò¶q¥Á²³°·±dÅv·í¤¤ª¾±¡ªºÅv§Q¡A¥]§t¹ï©óÀËÅ礧¥\¥Î©ÎÀËÅ礧¥Øªº¡BÀËÅçµ²ªG·Ç½T©Ê¡B¦³®Ä©Êµ¥«~½èºÊ±±¡B¤ÎÀËÅçµ²ªG¨Ï¥Î¤§¨îµ¥¡F¨ä¦¸¡A¹ï©óÀËÅ餧«O¦s¡B¾P·´¡B©Î¦A§Q¥Î¡A¤]¯A¤Î¥Á²³±Ó·P©Ê¸ê°T¤§ºûÅ@¡B¥Á²³¹ï©ó¦Û¨°ò¦]¸ê°T¤§¦Û¥DÅv¤ÎÁA¸Ñ°ò¦]¸ê°T¤§ª¾±¡Åv¡C
Ãö©ó¡u®ø¶OªÌ°ò¦]ÀËÅç¡v(Direct to Consumer, DTC)¡A¥DºÞ¾÷Ãö±N±¹ïªº¬O¦p¦ó¦Xªk¤Î¦³®ÄºÞ²z¡AÁ×§Kªk³W³Îµõ¾A¥Î¡A¥H¤ÎÂåÀøªk»PÂ卯¤Hû¹ï©ó¾Þ§@¤Hû©Ò«ß©w¤§¾Aªk©Ê°ÝÃD¡A±q¹êÅç«ÇºÝ«~½èªº±±ºÞ¡A¨ì®ø¶OªÌºÝªº¼s§i¡B³ø§i¸ÑÄÀ¡B¦¬¶O¾÷¨î¡A¨ä»PÂå¾ÇÀËÅ礧¤À§O»P¨î¡A¥H¤Î¬ÛÃö²£«~³d¥ô¡B®ø¶O¦æ¬°³d¥ô¤§Âç²M¡F¦AªÌ¡A¦p¥Ñ«DÂ卯¤Hûª½±µ±¹ï®ø¶OªÌ¡A¬O§_¯à½T«O®ø¶OªÌÀò±o¤@©w«O»Ù¡A¦p¦óÁ×§K²£¥Í½Ñ¦h¶Ã¶H¡AÀ³¬O¥DºÞ¾÷Ãö¦b«Øºc¾ãÅéªk¨î³W½dªº«ÂI¦Ò¶q¡C
Á`¤§¡A°ò¦]ÀËÅçªA°È»Ýn¦Ò¼{¨ä¤£¦P¥Øªº»P¤ÀÃþ¤è¦¡¡BÀËÅç¤èªk½ÆÂø«×¡BÀËÅçµ²ªG·ÀI¼h¯Å¥~¡A¦U¶µÀËÅ窺¹ê¥Î©Ê»P¨î©Ê¤]À³¨üÄYÂÔ¬dÃҤ覡©ÒºÞ¨î¡A¥»¤å´Á«Ý¥¼¨Ó¥DºÞ¾÷Ãö³z¹L¦X©yªºªk³W¤Î¦æ¬FºÊºÞ¾÷¨î¡A½T«OÀËÅç·Ç½T©Ê¤ÎÀËÅçªA°È¦³®Ä©Ê¡A¬°¥Á²³°·±dÅv¯q§âÃö¡C
·Qn¾\Äý§@ªÌ¼¶¼gªº§ó¦hÀù¯g¸ê°T¡AÅwªï«e©¹¥x¤¤¥«¥þ¤è¦ìÀù¯gÃöÃh¨ó·|©xºôhttp://www.cancerinfotw.org/¡A¨ÃÀµ½Ð¦U¦ì¯à°÷¥[¤J¨ó·|©x¤èfacebook¯»µ·¹Î¡A±N·R¤ßÃöÃh»Pª¾ÃѪº¤O¶q¶Ç»¼¥X¥h¡C¥[¤J¯»µ·¹Î¥i¥H©w´Á¾\Ū¨ì©xºôºë¿ï¤å³¹¡BÂå¾Ç±Ð¨|¼v¤ù¡A¨Ã¥B¨CӤ볣¥i¥H±µ¨ì¨ó·|ªº¹q¤l³ø±MÃD³ø¾É¡AÅýÀù¯g·sª¾¡u¤£¿òº|¡v
·QnÁA¸Ñ§@ªÌªº¸ê°T¤]½Ð¦Ühttp://cancerfree.medicalmap.tw/ ÂI¾\¡¨³¯Â@¶hÂå®v²¤¶¡¨
¬ÛÃöÂåÀøªA°È¸ê°T: ³¯Â@¶hÂå®vªù¶EªA°È®É¬q (2019.12.01¤½§i) http://cancerfree.medicalmap.tw/bencandy.php?fid=156&aid=4162
Àù¤Í¥²³Æ±M®Ñ Áo©úÀ»°hÀù¯h¾Î
Åý§A§ÜÀù¨Æ¥b¤S¥\¿
https://www.commonhealth.com.tw/book/bookTopic.action?nid=37
©µ¦ù¾\Ū:
|